In patients with WFA-sialylated MUC1 levels <900 μL/mL, 83% of patients had recurrence of HCC at BCLC stage 0 or A. On the other hand, in patients with WFA-sialylated MUC1 levels ≥900 μL/mL, 42% of patients had recurrence of HCC at BLCL stage B, C, or D, and these patients had poor recurrence of HCC (p = 0.02). The gene discussed is MUC1; the disease is hepatocellular carcinoma.